SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
MEDX 31.58+1.4%Nov 5 12:44 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (1816)9/10/2007 2:20:36 PM
From: scaram(o)uche  Read Replies (1) of 2240
 
I've been outspoken, since landing at S.I., about trials that are designed to enhance the immune response to antigens that, IMO, simply don't exist. And I've been able to predict, with 100% success, which trials would fail.

So....... it should be obvious that I expect the monotherapy trial to fail.

But a 10% response rate would be huge, particularly if there is a strong correlation with autoimmune-like side effects. The mab would coast through advisory committee and FDA approval.

I hold a small number of shares. The 010 concept originated in the lab of Jim Allison. It's a sincere, well-conceived effort to break tolerance to any antigen that might characterize a cancer. EVERYONE should be pulling for the company, and fund managers who are short are simply 9/11 whores.

While I generally appreciate Feuerstein's analyses, there's no doubt that he does rub elbows with the PRIMARY 9/11 whores and that he's done such since initial insult.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News